Description

Natera’s Unseen Growth Lever: Japan Could Open A New Signatera Chapter!

Natera reported first-quarter 2026 revenues of $697 million, representing a 39% year-over-year increase and marking the first quarter with over 1 million units delivered. This growth was driven primarily by strong performances in both women’s health and oncology segments. The company highlighted the successful launch of Fetal Focus, a single-gene non-invasive prenatal test (NIPT) powered by LinkedSNP technology, which has quickly gained traction with nearly a 200,000 annualized run rate of orders. This launch has added momentum to women’s health revenue growth alongside established Panorama and Horizon tests. Oncology volumes were robust, with clinical oncology units reaching 249,000—up 55% year-over-year and setting a new quarterly record. This growth was supported by new clinical data across multiple cancer types including bladder, colorectal, breast, and lymphoma, which have contributed to increasing physician adoption. Integration with OncoEMR systems and expansion of the commercial sales force have further enhanced ordering volumes.